Aiforia Technologies (AIFORIA) Q2 2025 earnings summary

Executive summary

• Order book increased 58% year-over-year to €5.1 million, fueled by strong demand for AI-assisted image analysis and clinical segment momentum.

• Major clinical customer wins in Europe, including NHS, Memorial Hospitals Group (Turkey), Fimlab (Finland), and key regions in Italy and France, with expansion supported by IVDR certification and strategic partnerships.

• Regulatory progress with IVDR certification enabled the largest CE-IVD-marked solution portfolio and rapid introduction of new AI models.

• Commercial momentum accelerated through new clinical agreements, reseller collaborations, and an €8 million share issue to fund growth.

• Strategic focus on scaling clinical business, leveraging flagship hospital references, and expanding in Europe.

Financial highlights

• Revenue grew 2% year-over-year to €1.4 million, with clinical business up 60% and group EBITDA improving to -€3 million.

• EBIT improved to -€5.4 million from -€6.1 million year-over-year.

• Cash and cash equivalents at period end were €11.9 million, down from €17.9 million.

• Gross investments, mainly in product development, totaled €3.6 million.

• Average number of employees decreased to 69, with new hires planned.

Outlook and guidance

• Stronger revenue recognition expected in H2 as major deals move to delivery phase.

• Continued focus on expanding clinical portfolio, maximizing European opportunities, and investing in product development and commercialization.

• Long-term plans include global market entry and prognostic AI applications.

• Healthy business pipeline and promising market conditions anticipated to support future growth.

• Management committed to becoming a global leader in AI-assisted pathology image analysis.